{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:17:09Z","timestamp":1788365829846,"version":"build-2803163510"},"reference-count":19,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jcyt.2026.102926","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:39:07Z","timestamp":1780720747000},"page":"102926","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Understanding FDA\u2019s reasons for nonapproval: A systematic review of complete response letters in cell and gene therapy"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5106-4010","authenticated-orcid":false,"given":"Eugene","family":"Babcock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1895-5600","authenticated-orcid":false,"given":"Cindy","family":"Riggins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2026.102926_bib0001","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jcyt.2019.04.002","article-title":"Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon","volume":"21","author":"Mendicino","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102926_bib0005","unstructured":"Confidentiality of data and information in applications for biologics licenses, 21 CFR \u00a7 601.51 (2023), [accessed 11.12.25]."},{"key":"10.1016\/j.jcyt.2026.102926_bib0006","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/JCE.0000000000000719","article-title":"FDA Embraces Transparency, Publishes Complete Response Letters","volume":"50","author":"Levin-Epstein","year":"2025","journal-title":"J Clin Eng"},{"key":"10.1016\/j.jcyt.2026.102926_bib0007","unstructured":"Trade secrets and commercial or financial information which is privileged or confidential, 21 CFR \u00a7 20.61 (2022), [accessed 11.12.25]."},{"key":"10.1016\/j.jcyt.2026.102926_bib0008","unstructured":"Availability for public disclosure of data and information in an application or abbreviated application, 21 CFR \u00a7 314.430 (2023), [accessed 11.12.25]."},{"key":"10.1016\/j.jcyt.2026.102926_bib0019","series-title":"Approved Cellular and Gene Therapy Products","year":"2023"},{"key":"10.1016\/j.jcyt.2026.102926_bib0009","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamainternmed.2020.8866","article-title":"Contents of US Food and Drug Administration refuse-to-file letters for new drug applications and efficacy supplements and their public disclosure by applicants","volume":"181","author":"Chahal","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jcyt.2026.102926_bib0010","series-title":"US Food and Drug Administration. Summary Basis for Regulatory Action: LANTIDRA","year":"2023"},{"key":"10.1016\/j.jcyt.2026.102926_bib0011","series-title":"US Food and Drug Administration. Summary Basis for Regulatory Action: ROCTAVIAN","year":"2023"},{"key":"10.1016\/j.jcyt.2026.102926_bib0012","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1001\/jama.2013.282542","article-title":"Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012","volume":"311","author":"Sacks","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jcyt.2026.102926_bib0013","doi-asserted-by":"crossref","first-page":"h2758","DOI":"10.1136\/bmj.h2758","article-title":"Comparison of content of FDA letters not approving applications for new drugs and associated public announcements from sponsors: cross sectional study","volume":"350","author":"Lurie","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.jcyt.2026.102926_bib0014","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/cts.12666","article-title":"The FDA\u2019s Regulatory Framework for Chimeric Antigen Receptor-T Cell Therapies","volume":"12","author":"Marks","year":"2019","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jcyt.2026.102926_bib0015","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1016\/j.xphs.2019.02.007","article-title":"Innovation in chemistry, manufacturing, and controls\u2014a regulatory perspective from industry","volume":"108","author":"Cauchon","year":"2019","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.jcyt.2026.102926_bib0016","doi-asserted-by":"crossref","first-page":"229","DOI":"10.18609\/cgti.2020.031","article-title":"The role of raw materials in the manufacturing of cell and gene therapy medicinal products: practices and challenges","volume":"6","author":"Caraballo","year":"2020","journal-title":"Cell Gene Ther Insights"},{"key":"10.1016\/j.jcyt.2026.102926_bib0017","article-title":"Key considerations in FDA prelicense inspections: ensuring compliance and quality in biomanufacturing","author":"Nassani","year":"2025","journal-title":"BioProcess Int"},{"key":"10.1016\/j.jcyt.2026.102926_bib0018","unstructured":"Biologics licenses; issuance and conditions, 21 CFR \u00a7 601.20 (2005)"},{"key":"10.1016\/j.jcyt.2026.102926_bib0020","series-title":"US Food and Drug Administration. Summary Basis for Regulatory Action: RYONCIL","year":"2024"},{"key":"10.1016\/j.jcyt.2026.102926_bib0021","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jcyt.2021.01.001","article-title":"Critical considerations for the development of potency tests for therapeutic applications of mesenchymal stromal cell-derived small extracellular vesicles","volume":"23","author":"Gimona","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102926_bib0022","series-title":"Demonstrating Substantial Evidence of Effectiveness With One Adequate and Well-Controlled Clinical Investigation and Confirmatory Evidence Guidance for Industry","year":"2023"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S146532492600887X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S146532492600887X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:24:25Z","timestamp":1788362665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S146532492600887X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S146532492600887X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102926","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding FDA\u2019s reasons for nonapproval: A systematic review of complete response letters in cell and gene therapy","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102926","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102926"}}